<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yu Y</submitter><funding>National Natural Science Foundation of China</funding><funding>China Postdoctoral Science Foundation</funding><funding>National Institutes of Health</funding><funding>NIH HHS</funding><pagination>e2307022</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10966566</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(12)</volume><pubmed_abstract>In clinics, hepcidin levels are elevated in various anemia-related conditions, particularly in iron-refractory anemia and in high inflammatory states that suppress iron absorption, which remains an urgent unmet medical need. To identify effective treatment options for various types of iron-refractory anemia, the potential effect of hypoxia and pharmacologically-mimetic drug FG-4592 (Roxadustat) are evaluated, a hypoxia-inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitor, on mouse models of iron-refractory iron-deficiency anemia (IRIDA), anemia of inflammation and 5-fluorouracil-induced chemotherapy-related anemia. The potent protective effects of both hypoxia and FG-4592 on IRIDA as well as other 2 tested mouse cohorts are found. Mechanistically, it is demonstrated that hypoxia or FG</pubmed_abstract><journal>Advanced science (Weinheim, Baden-Wurttemberg, Germany)</journal><pubmed_title>Activation of Intestinal HIF2α Ameliorates Iron-Refractory Anemia.</pubmed_title><pmcid>PMC10966566</pmcid><funding_grant_id>32200961</funding_grant_id><funding_grant_id>32200964</funding_grant_id><funding_grant_id>R01DK095201</funding_grant_id><funding_grant_id>82030003</funding_grant_id><funding_grant_id>M642414</funding_grant_id><funding_grant_id>32171166</funding_grant_id><funding_grant_id>31930057</funding_grant_id><funding_grant_id>31970689</funding_grant_id><funding_grant_id>32330047</funding_grant_id><funding_grant_id>2022M712749</funding_grant_id><pubmed_authors>Wu Q</pubmed_authors><pubmed_authors>Wang F</pubmed_authors><pubmed_authors>Lin Z</pubmed_authors><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Das NK</pubmed_authors><pubmed_authors>Min J</pubmed_authors><pubmed_authors>Sun S</pubmed_authors><pubmed_authors>Shah YM</pubmed_authors><pubmed_authors>Su Y</pubmed_authors><pubmed_authors>Yue W</pubmed_authors><pubmed_authors>Yang S</pubmed_authors><pubmed_authors>Yu Y</pubmed_authors><pubmed_authors>Zhou J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Activation of Intestinal HIF2α Ameliorates Iron-Refractory Anemia.</name><description>In clinics, hepcidin levels are elevated in various anemia-related conditions, particularly in iron-refractory anemia and in high inflammatory states that suppress iron absorption, which remains an urgent unmet medical need. To identify effective treatment options for various types of iron-refractory anemia, the potential effect of hypoxia and pharmacologically-mimetic drug FG-4592 (Roxadustat) are evaluated, a hypoxia-inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitor, on mouse models of iron-refractory iron-deficiency anemia (IRIDA), anemia of inflammation and 5-fluorouracil-induced chemotherapy-related anemia. The potent protective effects of both hypoxia and FG-4592 on IRIDA as well as other 2 tested mouse cohorts are found. Mechanistically, it is demonstrated that hypoxia or FG</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2025-04-25T21:33:49.445Z</modification><creation>2025-04-06T08:48:24.207Z</creation></dates><accession>S-EPMC10966566</accession><cross_references><pubmed>38243847</pubmed><doi>10.1002/advs.202307022</doi></cross_references></HashMap>